State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop.

Autor:	Schuind AE; PATH, Washington DC, United States., Rees H; Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa., Schiller J; National Cancer Institute, National Institutes of Health, Bethesda, United States., Mugo N; Kenya Medical Research Institute, Nairobi, Kenya and Department of Global Health, University of Washington, Seattle, United States., Dull P; Vaccine Development, Bill & Melinda Gates Foundation, Seattle, United States., Barnabas R; Division of Infectious Diseases, Mass General Hospital, Harvard Medical School, Boston, United States., Clifford GM; Early Detection, Prevention, and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France., Liu G; Department of Global Health, University of Washington, Seattle, United States., Madhi SA; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Johannesburg, South Africa., Morse RB; Centre of Vaccinology, University of Geneva, Switzerland., Moscicki AB; Department of Pediatrics, University of California Los Angeles, Los Angeles, United States., Palefsky JM; University of California, San Francisco School of Medicine, San Francisco, United States., Plotkin S; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States., Sierra MS; National Cancer Institute, National Institutes of Health, Bethesda, United States., Slifka MK; Oregon Health & Science University, Beaverton, United States., Vorsters A; Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium., Kreimer AR; National Cancer Institute, National Institutes of Health, Bethesda, United States., Didierlaurent AM; Centre of Vaccinology, University of Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	Preventive medicine reports [Prev Med Rep] 2023 Jul 19; Vol. 35, pp. 102331. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).
DOI:	10.1016/j.pmedr.2023.102331
Abstrakt:	The burden of cervical cancer is disproportionately distributed globally, with the vast majority of cases occurring in low- and middle-income countries. Women with human immunodeficiency virus (HIV) (WWH) are at increased risk of human papillomavirus (HPV) infection and cervical cancer as compared to HIV-negative individuals. HPV vaccination remains a priority in regions with a high burden of cervical cancer and high HIV prevalence. With HPV vaccines becoming more accessible, optimal use beyond the initial World Health Organization-recommended target population of 9 to 14-year-old girls is an important question. In March 2022, a group of experts in epidemiology, immunology, and vaccinology convened to discuss the state-of-the-science of HPV vaccination in WWH. This report summarizes the proceedings: review of HIV epidemiology and its intersection with cervical cancer burden, immunology, HPV vaccination including reduced-dose schedules and experience with other vaccines in people with HIV (PWH), HPV vaccination strategies and knowledge gaps, and outstanding research questions. Studies of HPV vaccine effectiveness among WWH, including duration of protection, are limited. Until data from ongoing research is available, the current recommendation for WWH remains for a multi-dose HPV vaccination regimen. A focus of the discussion included the potential impact of HIV acquisition following HPV vaccination. With no data currently existing for HPV vaccines and limited information from non-HPV vaccines, this question requires further research. Implementation research on optimal HPV vaccine delivery approaches for WWH and other priority populations is also urgently needed. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AMD reports participation in advisory boards for Sanofi, Bioaster, Speranza and ACM Biolabs, and research grants from GlaxoSmithKline, Moderna, and Roche, outside the submitted work. ABM reports personal fees from Merck & Co. global advisory board honorarium, outside the submitted work. GL is an employee of Merck & Co. NM is a recipient of an Investigator Initiated Grant evaluating ‘Immunogenicity of HPV vaccine among HIV infected adolescents’, outside the submitted work. JMP reports grants and personal fees from Merck & Co., from Vir Biotechnologies, from Antiva Biosciences, from Roche Diagnostics, and other from Virion Therapeutics, outside the submitted work. JS reports participation to DSMB for NCT04508309 and the India/IARC Gardasil trial. SAM reports grants from Bill & Melinda Gates Foundation, Pfizer, GlaxoSmithKline, Minervax and Sanofi, outside the submitted work. SP reports personal fees from Merck & Co. global advisory board honorarium, and personal fees from Sanofi, Inovio, Merck & Co., Janssen, Moderna, Valneva, Codagenix, Pfizer, VaxArt, Meissa, Vaxinnity, Rational, and AstraZeneca, outside the submitted work. RB reports grants from National Institutes of Health and Bill & Melinda Gates Foundation and non-financial support from Regeneron Pharmaceutical, outside the submitted work. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu